Alivus Life Sciences Limited (ALIVUS.NS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yasir Yusufali Rawjee Ph.D. | CEO, MD & Director | 272.35M | -- | 1965 |
| Mr. Tushar P. Mistry | Senior VP & CFO | -- | -- | -- |
| Mr. Vinod Naik | Group VP, Head of Technical Operations & Whole Time Director | 56.56M | -- | -- |
| Mr. Rudalf Corriea | Company Secretary & Compliance Officer | -- | -- | -- |
| Soumi Rao | General Manager of Corporate Communications | -- | -- | -- |
| Mr. Sumantra Mitra | Senior VP & Head of Human Resources | 18.2M | -- | -- |
| Mr. Mathew George | Senior VP & Head of Regulatory Affairs | -- | -- | -- |
| Mr. Navin Kumar Agrawal | VP & Head of Corporate Quality | -- | -- | -- |
Alivus Life Sciences Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 2,014
Description
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
October 17, 2023 at 12:00 AM UTC
Ex-Dividend Date